Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Tony, Tarragona"'
1
Akademický článek
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Autor: Michael C Keefer, Jill Gilmour, Peter Hayes, Dilbinder Gill, Jakub Kopycinski, Hannah Cheeseman, Michelle Cashin-Cox, Marloes Naarding, Lorna Clark, Natalia Fernandez, Catherine A Bunce, Christine M Hay, Sabrina Welsh, Wendy Komaroff, Lottie Hachaambwa, Tony Tarragona-Fiol, Eddy Sayeed, Devika Zachariah, James Ackland, Kelley Loughran, Burc Barin, Emmanuel Cormier, Josephine H Cox, Patricia Fast, Jean-Louis Excler
Publikováno v: PLoS ONE, Vol 7, Iss 8, p e41936 (2012)
We conducted a phase I, randomized, double-blind, placebo-controlled trial to assess the safety and immunogenicity of escalating doses of two recombinant replication defective adenovirus serotype 35 (Ad35) vectors containing gag, reverse transcriptas
Externí odkaz: https://doaj.org/article/89f3b5e64fb5427eae23022023f29d20
Zobrazit plný text záznamu
2
Akademický článek
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
Autor: Sandhya Vasan, Arlene Hurley, Sarah J Schlesinger, Drew Hannaman, David F Gardiner, Daniel P Dugin, Mar Boente-Carrera, Roselle Vittorino, Marina Caskey, Johanne Andersen, Yaoxing Huang, Josephine H Cox, Tony Tarragona-Fiol, Dilbinder K Gill, Hannah Cheeseman, Lorna Clark, Len Dally, Carol Smith, Claudia Schmidt, Harriet H Park, Jakub T Kopycinski, Jill Gilmour, Patricia Fast, Robert Bernard, David D Ho
Publikováno v: PLoS ONE, Vol 6, Iss 5, p e19252 (2011)
DNA-based vaccines have been safe but weakly immunogenic in humans to date.We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP
Externí odkaz: https://doaj.org/article/54e6c0214ce848db98e3291e78e074a0
Zobrazit plný text záznamu
3
Akademický článek
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
Autor: Dilbinder K Gill, Yunda Huang, Gail L Levine, Anna Sambor, Donald K Carter, Alicia Sato, Jakub Kopycinski, Peter Hayes, Bridget Hahn, Josephine Birungi, Tony Tarragona-Fiol, Hong Wan, Mark Randles, Andrew Raxworthy Cooper, Aloysius Ssemaganda, Lorna Clark, Pontiano Kaleebu, Steven G Self, Richard Koup, Blake Wood, M Juliana McElrath, Josephine H Cox, John Hural, Jill Gilmour
Publikováno v: PLoS ONE, Vol 5, Iss 12, p e14330 (2010)
The Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) was created to provide standardized immunogenicity monitoring services for HIV vaccine trials. The ex vivo interferon-gamma (IFN-γ) ELISpot is used extensively as a primary imm
Externí odkaz: https://doaj.org/article/d7ee610eb88e43178a1408e4a5529118
Zobrazit plný text záznamu
4
Akademický článek
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Autor: Walter Jaoko, Etienne Karita, Kayitesi Kayitenkore, Gloria Omosa-Manyonyi, Susan Allen, Soe Than, Elizabeth M Adams, Barney S Graham, Richard A Koup, Robert T Bailer, Carol Smith, Len Dally, Bashir Farah, Omu Anzala, Claude M Muvunyi, Jean Bizimana, Tony Tarragona-Fiol, Philip J Bergin, Peter Hayes, Martin Ho, Kelley Loughran, Wendy Komaroff, Gwynneth Stevens, Helen Thomson, Mark J Boaz, Josephine H Cox, Claudia Schmidt, Jill Gilmour, Gary J Nabel, Patricia Fast, Job Bwayo
Publikováno v: PLoS ONE, Vol 5, Iss 9, p e12873 (2010)
BackgroundWe conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as
Externí odkaz: https://doaj.org/article/e14cd23e1bda4c33ac138fcbe3751b52
Zobrazit plný text záznamu
7
Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials
Autor: Jill Gilmour, Josephine Birungi, Harr Freeya Njai, Ben Gombe, Tomusange Khamis, Dareskedar Admassu, Pontiano Kaleebu, Anatoli Kamali, Eugene Ruzagira, Gwynneth Stevens, Tony Tarragona-Fiol, Joseph Mugisha, Kholoud Porter
Publikováno v: Laboratory Medicine. 42:711-718
Despite infrastructure and capacity challenges in Africa, significant development has been made in the number of laboratories supporting immunological and safety studies required for large-scale HIV/AIDS vaccine or intervention trials. In Uganda, coh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c5b0880194ae890f3c49c5076325f3d
https://doi.org/10.1309/lm84wweuskt4abxo
Zobrazit plný text záznamu
8
Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects
Autor: Jill Gilmour, A. Guimarães-Walker, Tomáš Hanke, G Hancock, Peter Hayes, Anne Bridgeman, Andrew J. McMichael, Lucy Dorrell, K di Gleria, Tony Tarragona-Fiol, Sarah A. Howles, Hongbing Yang
Publikováno v: Vaccine. 28:7306-7312
We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell respon
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30365ce9fcfae445e06c64b91ebf5ad7
https://doi.org/10.1016/j.vaccine.2010.08.077
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje